Inflarx N V (IFRX)

May 05, 2025

Geode Capital Management LLC Grows Stake in InflaRx (NASDAQ:IFRX) - Defense World

May 05, 2025

May 04, 2025

InflaRx To Reveal Next Month Its Late-Stage Interim Results Of Lead Drug In Painful Ulcer - RTTNews

May 04, 2025

May 02, 2025

InflaRx (NASDAQ:IFRX) Earns Overweight Rating from Analysts at Cantor Fitzgerald - Defense World

May 02, 2025

May 02, 2025

Cantor Fitzgerald Predicts InflaRx FY2025 Earnings - Defense World

May 02, 2025

May 02, 2025

InflaRx (IFRX) Projected to Post Quarterly Earnings on Wednesday - Defense World

May 02, 2025

May 01, 2025

What is InflaRx N.V (IFRX) Stock Return on Shareholders’ Capital? - Sete News

May 01, 2025

Apr 30, 2025

Checking in on InflaRx N.V (IFRX) after recent insiders movement - knoxdaily.com

Apr 30, 2025

Apr 30, 2025

InflaRx N.V (IFRX) Stock: The Story of a 52-Week Stock Range - investchronicle.com

Apr 30, 2025

Apr 30, 2025

InflaRx N.V (IFRX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com

Apr 30, 2025

Apr 30, 2025

InflaRx to Report First Quarter 2025 Results on May 7, 2025 - GlobeNewswire

Apr 30, 2025

Apr 30, 2025

InflaRx, Pioneer in Anti-Inflammatory Therapeutics, Announces Q1 2025 Earnings Date - Stock Titan

Apr 30, 2025

Apr 30, 2025

Cantor Fitzgerald Initiates Coverage of InflaRx N.V. (IFRX) with Overweight Recommendation - MSN

Apr 30, 2025

Apr 29, 2025

Cantor Fitzgerald sets $10 target for Inflarx stock, cites catalysts By Investing.com - Investing.com South Africa

Apr 29, 2025

Apr 29, 2025

Biotech Shares Jump As Institutional Coverage Begins With Positive Outlook - The Globe and Mail

Apr 29, 2025

Apr 29, 2025

Cantor Fitzgerald sets $10 target for Inflarx stock, cites catalysts - Investing.com

Apr 29, 2025

Apr 29, 2025

Cantor Fitzgerald Initiates InflaRx at Overweight $10 Price Target - marketscreener.com

Apr 29, 2025

Apr 28, 2025

InflaRx (IFRX) Projected to Rise with Upcoming Phase 3 Data Rele - GuruFocus

Apr 28, 2025

Apr 25, 2025

InflaRx Approves Key Resolutions at Annual Shareholder Meeting - MSN

Apr 25, 2025

Apr 13, 2025

InflaRx launches public offering of shares and warrants - MSN

Apr 13, 2025

Apr 09, 2025

Commonwealth Equity Services LLC Has $275,000 Stock Holdings in InflaRx (NASDAQ:IFRX) - Defense World

Apr 09, 2025

Apr 03, 2025

InflaRx N.V. Announces 2025 Annual General Meeting Agenda - TipRanks

Apr 03, 2025

Apr 02, 2025

Raymond James Financial Inc. Purchases Shares of 638,092 InflaRx (NASDAQ:IFRX) - Defense World

Apr 02, 2025

Mar 28, 2025

Guggenheim Forecasts Strong Price Appreciation for InflaRx (NASDAQ:IFRX) Stock - Defense World

Mar 28, 2025

Mar 27, 2025

Guggenheim raises Inflarx stock target to $10, maintains Buy rating By Investing.com - Investing.com Australia

Mar 27, 2025

Mar 26, 2025

InflaRx price target raised to $10 from $7 at Guggenheim - TipRanks

Mar 26, 2025

Mar 26, 2025

InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Mar 26, 2025

Mar 26, 2025

Guggenheim raises Inflarx stock target to $10, maintains Buy rating - Investing.com India

Mar 26, 2025

Mar 23, 2025

HC Wainwright Reiterates “Buy” Rating for InflaRx (NASDAQ:IFRX) - Defense World

Mar 23, 2025

Mar 21, 2025

InflaRx N.V. Reports 2024 Results and Key Achievements - TipRanks

Mar 21, 2025

Mar 20, 2025

InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025

Mar 20, 2025

InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval - MSN

Mar 20, 2025

Mar 20, 2025

InflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last year - TipRanks

Mar 20, 2025

Mar 20, 2025

InflaRx Reports 2024 Results and Outlines 2025 Milestones - TipRanks

Mar 20, 2025

Mar 20, 2025

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones - GlobeNewswire

Mar 20, 2025

Mar 20, 2025

InflaRx 2024 Earnings Reveal Strong Cash Position and Major EU Drug Win - StockTitan

Mar 20, 2025

Mar 16, 2025

Short Interest in InflaRx (NASDAQ:IFRX) Grows By 46.2% - Defense World

Mar 16, 2025

Mar 13, 2025

InflaRx (IFRX) Projected to Post Earnings on Thursday - Defense World

Mar 13, 2025

Mar 11, 2025

InflaRX Presents Efficacy and Safety Data on Vilobelimab at AAD 2025 - Dermatology Times

Mar 11, 2025

Mar 09, 2025

InflaRx (NASDAQ:IFRX) Earns Buy Rating from HC Wainwright - Defense World

Mar 09, 2025

Mar 07, 2025

InflaRx announces presentation of multiple posters on utility of vilobelimab - TipRanks

Mar 07, 2025

Mar 07, 2025

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewswire

Mar 07, 2025

Mar 07, 2025

Can This Drug Transform Hidradenitis Suppurativa Treatment? New Data Shows 3x Better Results - StockTitan

Mar 07, 2025

Feb 28, 2025

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewswire

Feb 28, 2025

Feb 28, 2025

Can InflaRx's Vilobelimab Transform Treatment for These Rare Skin Diseases? - StockTitan

Feb 28, 2025

Feb 25, 2025

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences - GlobeNewswire

Feb 25, 2025

Feb 25, 2025

InflaRx N.V. to Release Fourth Quarter 2024 Financial Results and Participate in Key Investor Conferences - Nasdaq

Feb 25, 2025

Feb 25, 2025

InflaRx Financial Results Coming March 20: What's Next for this Anti-Inflammatory Therapeutics Developer? - StockTitan

Feb 25, 2025

Feb 20, 2025

Short Interest in InflaRx (NASDAQ:IFRX) Decreases By 13.7% - MarketBeat

Feb 20, 2025

Feb 18, 2025

InflaRx Concludes $30 Million Public Offering - TipRanks

Feb 18, 2025

Feb 18, 2025

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire

Feb 18, 2025

Feb 14, 2025

InflaRx commences offering of ordinary shares and pre-funded warrants - MSN

Feb 14, 2025